Cargando…
Efficacy and safety of an innovative short-course regimen containing clofazimine for treatment of drug-susceptible tuberculosis: a clinical trial
In preclinical studies, a new antituberculosis drug regimen markedly reduced the time required to achieve relapse-free cure. This study aimed to preliminarily evaluate the efficacy and safety of this four-month regimen, consisting of clofazimine, prothionamide, pyrazinamide and ethambutol, with a st...
Autores principales: | Zheng, Xubin, Gui, Xuwei, Yao, Lan, Ma, Jun, He, Yifan, Lou, Hai, Gu, Jin, Ying, Ruoyan, Chen, Liping, Sun, Qin, Liu, Yidian, Ho, Chih-Ming, Lee, Bai-Yu, Clemens, Daniel L., Horwitz, Marcus A., Ding, Xianting, Hao, Xiaohui, Yang, Hua, Sha, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026740/ https://www.ncbi.nlm.nih.gov/pubmed/36872899 http://dx.doi.org/10.1080/22221751.2023.2187247 |
Ejemplares similares
-
Designing molecular diagnostics for current tuberculosis drug regimens
por: Georghiou, Sophia B., et al.
Publicado: (2023) -
What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis
por: Stagg, H R, et al.
Publicado: (2016) -
Treatment outcomes of patients with MDR-TB in Nepal on a current programmatic standardised regimen: retrospective single-centre study
por: Ghimire, Samiksha, et al.
Publicado: (2020) -
Adjunctive Zoledronate + IL-2 administrations enhance anti-tuberculosis Vγ2Vδ2 T-effector populations, and improve treatment outcome of multidrug-resistant tuberculosis(1)
por: Shen, Hongbo, et al.
Publicado: (2022) -
Prompt recognition of infectious pulmonary tuberculosis is critical to achieving elimination goals: a retrospective cohort study
por: Heffernan, Courtney, et al.
Publicado: (2020)